Research

Global Clinical Trials, Research, Regulation and Education

October 2015

Authors:

It may not be preposterous to accept that two major industrial technologies changed human lives in the past fifty years. The first being information technology (IT). IT revolutionized the speed and quality of communication information essential for the evolution of human beings materially and spiritually. The second being the pharmaceutical industry, that redefined the quality of life by providing solutions to curb or cure dreadful diseases and, maintain the fountain of youth. Stringent strategic, economic and regulatory practices, favoured venture of the pharmaceutical industries in to developing regions of the world, outside the US, Canada and Europe. Clinical trials, an integral part of new pharmaceutical and medical device development soon followed the global pursuit of the industry

ResearchGate has not been able to resolve any citations for this publication.

ResearchGate has not been able to resolve any references for this publication.

Article

As the Pendulum Swings--Medical Products Class Actions Litigation in Canada: Recent Developments

March 2013 · Journal of Diabetes Science and Technology

During the relatively short history of class proceedings in Canada, developers and manufacturers of medical devices and pharmaceuticals ("medical products"), including medical products designed for patients with diabetes, have found themselves at the receiving end of a significant number of class action claims. As a result, medical products litigation has become the battleground for some of the ... [Show full abstract] most significant developments in Canadian class actions law. This article provides a broad overview of some of the most significant developments. The authors pay particular attention to developments regarding the test for class action certification and consider whether high-profile dismissals of certification motions represent a trend toward raising the threshold for plaintiffs seeking to obtain certification of a proposed class action. The authors also consider a decision arising out of a lengthy class action common issues trial in which the medical device company was victorious. In the authors' view, the class action pendulum in Canada, particularly as it relates to medical products claims, remains in motion. It behooves all affected players to keep their eye on this ball with rapt attention to see where it may move next.

Chapter

European Federation of Statisticians in the Pharmaceutical Industry (EFPSI)

July 2005

The Federation is open to nationally constituted groups of statisticians who are working in or for the pharmaceutical industry. The Federation was constituted in 1992, and in 2004, includes eleven member groups. EFSPI is engaged in statistical aspects of research, development, production, and postmarketing surveillance of drugs, biologics, and medical ... [Show full abstract] devices. Keywords: EFSPI; pharmaceutical; Europe; guidelines; regulation

Article

The Regulatory Environment for the New Millennium

July 2000 · Therapeutic Innovation and Regulatory Science

Steven F. Hoff

Changes in the global regulatory environment for the pharmaceutical and medical device industries are having a significant impact on how new products are developed and marketed. Throughout the 1990s, major efforts in global harmonization of regulatory requirements were made by several organizations. In the pharmaceutical industry, the many new guidelines for quality, safety, and efficacy are ... [Show full abstract] being implemented in Europe, Japan, and the United States, while work continues to develop the Common Technical Document for the format and content of new market applications. In the medical device industry, the implementation of the European CE Mark and the work of the Global Harmonization Task Force is revolutionizing the regulatory environment. These global efforts along with the national movements to reorganize local regulatory environments in Europe and the United States are discussed.

Article

The regulatory environment for the new millennium

July 2000 · Drug Information Journal

SF Hoff

Changes in the global regulatory environment for the pharmaceutical and medical device industries are having a significant impact on how new products are developed and marketed. Throughout the 1990s, major efforts in global harmonization of regulatory requirements were made by several organizations, ht the pharmaceutical industry, the many new guidelines for quality, safety and efficacy are being ... [Show full abstract] implemented in Europe, Japan, and the United States, while work continues to develop the Common Technical Document for the format and content of new market applications. rn the medical device industry, the implementation of the European CE Mark and the work of the Global Harmonization Task Force is revolutionizing the regulatory environment. These global efforts along with the national movements to reorganize focal regulatory environments in Europe and the United States are discussed.

Article

Full-text available

An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?

March 2019 · The European Journal of Health Economics

An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative effectiveness assessment (REA) for pharmaceuticals and medical devices. This cooperation is operationalised through a proposal for a regulation. While a good step in the right direction, this HTA cooperation framework needs to be more explicit and pragmatic about clinical value definition, ... [Show full abstract] what constitutes quality of evidence, how real-world evidence is handled, whether the same assessment requirements will apply for medical devices as they do for pharmaceuticals, and how to safeguard consistency in REA interpretation. If demand-rather than supply-driven, this initiative can deliver wider benefits: Europe can improve its power in global drug design and development, while Member States will have at their disposal more resources to assess performance of interventions in their healthcare systems.

Article

Managing for excellence in the pharmaceutical industry: Outsourcing to contract research organizatio...

June 2008

This article discusses the pharmaceutical industry and the outsourcing work to contract research organizations (CRO). It provides background information on the industry and the CRO and discusses the benefits a pharmaceutical company can realize through use of a CRO for manufacturing or clinical trials. It also informs the reader of a number of issues that a company must consider as part of the ... [Show full abstract] decision-making process. It concludes that CROs and outsourcing are useful to pharmaceutical companies for decreasing project costs by carefully selecting CROs, and good planning will result in successful projects that save money and decrease the time for a drug to pass from discovery to market.

Article

Fundación SERMES para la Investigación Clínica

September 2014 · Medicina y Seguridad del Trabajo

Josefina Berlanga

SERMES se constituyó en 1997 como un Centro Especial de Empleo, con una plantilla inicial de siete trabajadores con experiencia en grabación y proceso de datos. Su objetivo principal siempre ha sido la integración laboral de personas con discapacidad. En 2001 cuando se fundó SERMES CRO™ para apoyar el desarrollo y crecimiento de la empresa en todas las actividades relacionadas con Investigación ... [Show full abstract] Clínica. Con el objetivo de ampliar la cartera de clientes internacionales y dar servicio clientes locales en proyectos internacionales, SERMES CRO funda PSN con oficinas centrales en EEUU y subsidiarias en España, Francia, Inglaterra, Alemania, Italia, Holanda y Dinamarca además de tener acuerdos de colaboración con otras compañías para cubrir aquellos países en los que no se posee de oficinas propias. PSN es una CRO global que ofrece a empresas farmacéuticas, biotecnológicas e instituciones independientes una alternativa flexible, rápida, de calidad y coste-efectiva. Por otro lado, se ha creado SERMES UK, en Inglaterra, con el fin de ofrecer la representación legal a promotores sin filial ni ubicación física en la Unión Europea (UE) y aprovechar las sinergias propias de una localización en Inglaterra. Dicha representación, conocida como "representación legal", es válida para los ensayos clínicos con medicamentos, así como los ensayos clínicos de dispositivos médicos. Para más información sobre Fundación Sermes para la Investigación Clínica, por favor contactar: Tel 91.375.69.30 - Fax 91.375.69.31 info@fundacionsermes.org www.fundacionsermes.org www.sermescro.com www.psnglobal.org.

Article

Full-text available

Combinational products: A regulatory review

November 2010 · International Journal of Pharmaceutical Sciences Review and Research

A regulation with respect to combination products and FDA over view. Advances in drug, biologic and medical device development relate to both single entities and combination of each type of medicinal product. Regulatory overview of combination products is complicated by the fact that although drugs are regulated primarily under section 505 of Food, drugs and cosmetic act and reviewed by CDER, ... [Show full abstract] CBER, and CDRH. Combination products increasingly include state-of-art, innovative technologies with great potential to advance patient care. Combining different regulated product types, however, triggers a panoply of issues with which the Food and Drug Administration, pharmaceutical, biologic and medical device manufacturers, and other stake holders have struggled through the years. Since 1991, FDA has worked toward resolving a number of these issues, and has made some inroads in assignment of jurisdiction for combination products. We are encouraged by FDA's preliminary efforts, and look forward to further improvement in the regulatory process for combination products.

Article

Polymers used for Pharmaceutical Packaging and Medical Devices Quality and supply assurance

January 2009 · Die Pharmazeutische Industrie

Gaby Reckzuegel

The following paper provides an overview on the regulatory, technical, and strategic requirements for polymers used for pharmaceutical packaging and medical devices and presents the de.nition and impact of material changes. Some of the working groups of pharmaceutical companies working on a common understanding of the pharmaceutical industry and their suppliers on these needs and requirements are ... [Show full abstract] introduced.

Article

Production capacity investment with data updates

March 2014 · IIE Transactions

This article presents a model of the capacity investment problem faced by pharmaceutical firms and other firms with long and risky product development cycles. These firms must balance two conflicting objectives: on one hand, the delay in scaling up production once the product is approved must be minimized and, on the other hand, the risk of investing in ultimately unused capacity must be ... [Show full abstract] minimized. A stylized model of this type of capacity investment problem is developed and analyzed. In this model the firm re-evaluates its capacity investment strategy as information about the potential success of the product is continually updated (for example, via clinical trial results in the case of the pharmaceutical industry). Motivated by observations of current practices in the biopharmaceutical industry, a computational study is used to explore how practices such as more frequent re-evaluations of investment decisions, stopping and restarting of projects, and the use of alternative types of capacity can, under certain conditions, help the firm reduce both the delay of the commercial launch of the new product and the risk of lost investment.

Article

An Approach to CDISC SDTM Implementation for Clinical Trials Data

January 1970

The Clinical Data Interchange Standards Consortium (CDISC) is a non-profit international organization estab- lished to define standard data formats to support the exchange of clinical data among and within organiza- tions such as pharmaceutical and medical device companies, contract research organizations, universities, medical research institutions, and regulatory agencies. The CDISC Study Data ... [Show full abstract] Tabulation Model (SDTM) defines the standard format for tabulation data. Generally, there are three approaches for implementing SDTM within the pharmaceutical industry: pure SDTM, submission-only, and database-only. The pure SDTM approach means all study data will be SDTM-compliant, starting from data capture and ending with data analysis and submission. The submission-only approach leaves the current practice alone and creates the SDTM-complaint datasets for submissions. The database-only approach feeds the study data into a clinical database, which is SDTM-compliant. This paper discusses the database-only approach to implementation of SDTM version 1.1 and SDTMIG (Implementation Guide) version 3.1.1 and explores the pros and cons of the current SDTM standard.

Article

An overview of the Common Technical Document (CTD) regulatory dossier

June 2014 · Medical Writing

Debbie Jordan

The Common Technical Document (CTD) was designed to provide a common format between Europe, USA, and Japan for the technical documentation included in an application for the registration of a human pharmaceutical product. The CTD dossier is divided into five main modules: Module 1 – Administrative information and prescribing information; Module 2 – Overviews and summaries of Modules 3–5; Module 3 ... [Show full abstract] – Quality (pharmaceutical documentation); Module 4: Non-clinical reports (pharmacology/toxicology); Module 5: Clinical study reports (clinical trials). Detailed guidelines are provided describing the content of each module and the majority of submissions must now follow the CTD format for submission dossiers.